These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30615343)

  • 1. [Impact of TAK-1 inhibition on tumor growth and bone destruction in myeloma].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():185-9. PubMed ID: 30615343
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloma bone disease.
    Sezer O
    Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.
    Bataille R; Chappard D; Marcelli C; Dessauw P; Sany J; Baldet P; Alexandre C
    J Clin Oncol; 1989 Dec; 7(12):1909-14. PubMed ID: 2585025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Myeloma bone disease and RANKL signaling].
    Abe M
    Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of bone lesions in multiple myeloma].
    Hata H; Mitsuya H
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
    Teramachi J; Hiasa M; Oda A; Harada T; Nakamura S; Amachi R; Tenshin H; Iwasa M; Fujii S; Kagawa K; Miki H; Kurahashi K; Yoshida S; Endo I; Haneji T; Matsumoto T; Abe M
    Br J Haematol; 2018 Feb; 180(4):581-585. PubMed ID: 27748523
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New agents in the Treatment of Myeloma Bone Disease.
    Ring ES; Lawson MA; Snowden JA; Jolley I; Chantry AD
    Calcif Tissue Int; 2018 Feb; 102(2):196-209. PubMed ID: 29098361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone hyperresorption in multiple myeloma].
    Beaudreuil J; Orcel P
    Presse Med; 2000 Mar; 29(9):492-7. PubMed ID: 10745943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone destruction in multiple myeloma.
    Matsumoto T; Abe M
    Ann N Y Acad Sci; 2006 Apr; 1068():319-26. PubMed ID: 16831932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bisphosphonates in the treatment of multiple myeloma].
    Stajszczyk M
    Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
    Terpos E; Politou M; Viniou N; Rahemtulla A
    Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
    Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
    Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
    Abe M
    Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of bone destruction in multiple myeloma.
    Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.
    Yang J; Liu Z; Liu H; He J; Yang J; Lin P; Wang Q; Du J; Ma W; Yin Z; Davis E; Orlowski RZ; Hou J; Yi Q
    Sci Signal; 2017 Dec; 10(509):. PubMed ID: 29233917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.